Forms a and b of n-2-2-(diaminomethylene)amino-4-thiazolylmethylthioethylaminomethylene-4-bromo-benzenesulfonamide
CA 2180378 C · Owner: Anglada Burniol, Lluis · Inventors: Anglada Burniol, Lluis; Sacristan Munoz, Aurelio; Foguet Ambros, Rafael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Ebrotidine is indicated for the treatment of duodenal ulceration, benign gastric or pre-pyloric peptic ulcer and, nonsteroidal anti-inflammatory drug-induced gastroduodenal lesions. Ebrotidine in combination with antibiotics is used for the eradication of Helicobacter pylori in duodenal ulcer patients.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 4, 1994 and granted August 20, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 4, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 4, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.